326 related articles for article (PubMed ID: 1733549)
1. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Vokes EE; Moormeier JA; Ratain MJ; Egorin MJ; Haraf DJ; Mick R; Weichselbaum RR
Cancer Chemother Pharmacol; 1992; 29(3):178-84. PubMed ID: 1733549
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
3. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
Vokes EE; Ratain MJ; Mick R; McEvilly JM; Haraf D; Kozloff M; Hamasaki V; Weichselbaum RR; Panje WR; Wenig B
J Clin Oncol; 1993 Feb; 11(2):360-8. PubMed ID: 8426214
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Vokes EE; Panje WR; Schilsky RL; Mick R; Awan AM; Moran WJ; Goldman MD; Tybor AG; Weichselbaum RR
J Clin Oncol; 1989 Jun; 7(6):761-8. PubMed ID: 2715806
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
O'Dwyer PJ; Cornfeld MJ; Peter R; Comis RL
Cancer Chemother Pharmacol; 1990; 27(2):131-4. PubMed ID: 2249328
[TBL] [Abstract][Full Text] [Related]
9. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.
Haraf DJ; Vokes EE; Weichselbaum RR; Panje WR
Laryngoscope; 1992 Jun; 102(6):630-6. PubMed ID: 1602911
[TBL] [Abstract][Full Text] [Related]
10. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Katori H; Tsukuda M; Taguchi T
Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.
Vokes EE; Haraf DJ; McEvilly JM; Mick R; Kozloff MF; Goldman MD; Moran WJ; Clendeninn NJ; Collier MA; Weichselbaum RR
Ann Oncol; 1992 Jan; 3(1):79-81. PubMed ID: 1606074
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Brockstein B; Haraf DJ; Stenson K; Fasanmade A; Stupp R; Glisson B; Lippman SM; Ratain MJ; Sulzen L; Klepsch A; Weichselbaum RR; Vokes EE
J Clin Oncol; 1998 Feb; 16(2):735-44. PubMed ID: 9469365
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
Vokes EE; Choi KE; Schilsky RL; Moran WJ; Guarnieri CM; Weichselbaum RR; Panje WR
J Clin Oncol; 1988 Apr; 6(4):618-26. PubMed ID: 3258629
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
Caponigro F; Comella P; Rivellini F; Avallone A; Budillon A; Di Gennaro E; Mozzillo N; Ionna F; De Rosa V; Manzione L; Comella G
Ann Oncol; 2000 May; 11(5):575-80. PubMed ID: 10907951
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.
Wendt TG; Grabenbauer GG; Rödel CM; Thiel HJ; Aydin H; Rohloff R; Wustrow TP; Iro H; Popella C; Schalhorn A
J Clin Oncol; 1998 Apr; 16(4):1318-24. PubMed ID: 9552032
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer.
Bhalla K; Birkhofer M; Bhalla M; Lutzky J; Hindenburg A; Cole J; Ince C
Am J Clin Oncol; 1991 Dec; 14(6):509-13. PubMed ID: 1957839
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
[TBL] [Abstract][Full Text] [Related]
19. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H
Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
